Mediwound Ltd (NASDAQ:MDWD) was the target of a large decrease in short interest in the month of June. As of June 30th, there was short interest totalling 32,900 shares, a decrease of 30.1% from the June 15th total of 47,100 shares. Based on an average trading volume of 130,700 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s shares are short sold.
Several equities research analysts recently issued reports on MDWD shares. Oppenheimer reissued a “buy” rating and issued a $7.00 target price on shares of Mediwound in a research report on Tuesday, June 30th. Zacks Investment Research upgraded shares of Mediwound from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Saturday, June 20th. Finally, HC Wainwright restated a “buy” rating and set a $5.50 price objective on shares of Mediwound in a report on Wednesday.
A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its stake in shares of Mediwound by 42.0% in the fourth quarter. Renaissance Technologies LLC now owns 407,408 shares of the biopharmaceutical company’s stock valued at $1,263,000 after buying an additional 120,508 shares in the last quarter. Acadian Asset Management LLC grew its stake in Mediwound by 136.4% during the 1st quarter. Acadian Asset Management LLC now owns 130,072 shares of the biopharmaceutical company’s stock worth $205,000 after buying an additional 75,045 shares during the last quarter. Fortis Advisors LLC bought a new position in shares of Mediwound in the first quarter worth $108,000. Sargent Investment Group LLC grew its stake in shares of Mediwound by 51.5% in the first quarter. Sargent Investment Group LLC now owns 117,400 shares of the biopharmaceutical company’s stock worth $184,000 after purchasing an additional 39,900 shares in the last quarter. Finally, Wells Fargo & Company MN grew its stake in shares of Mediwound by 15.8% in the first quarter. Wells Fargo & Company MN now owns 219,386 shares of the biopharmaceutical company’s stock worth $345,000 after purchasing an additional 29,911 shares in the last quarter. 22.86% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:MDWD remained flat at $$3.37 during trading on Friday. The stock had a trading volume of 271,032 shares, compared to its average volume of 246,418. The company has a 50-day moving average price of $2.24 and a 200-day moving average price of $2.42. The firm has a market capitalization of $91.67 million, a price-to-earnings ratio of 14.04 and a beta of 1.52. Mediwound has a 1-year low of $1.44 and a 1-year high of $4.14. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.89 and a current ratio of 3.08.
Mediwound (NASDAQ:MDWD) last announced its quarterly earnings results on Wednesday, May 20th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.05. Mediwound had a net margin of 18.46% and a negative return on equity of 75.91%. The firm had revenue of $4.44 million for the quarter, compared to analysts’ expectations of $4.25 million. On average, analysts expect that Mediwound will post -0.41 earnings per share for the current fiscal year.
Mediwound Company Profile
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.
Further Reading: Why Invest in Dividend Achievers?
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.